BNP Paribas Financial Markets Invests $1.66 Million in Bioventus Inc. (NYSE:BVS)

BNP Paribas Financial Markets bought a new stake in Bioventus Inc. (NYSE:BVS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 158,017 shares of the company’s stock, valued at approximately $1,659,000. BNP Paribas Financial Markets owned approximately 0.19% of Bioventus at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after purchasing an additional 1,786 shares in the last quarter. Plato Investment Management Ltd bought a new position in Bioventus during the 4th quarter valued at $38,000. KLP Kapitalforvaltning AS bought a new position in Bioventus during the 4th quarter valued at $75,000. Quantbot Technologies LP bought a new position in Bioventus during the 4th quarter valued at $103,000. Finally, Arizona State Retirement System bought a new position in Bioventus during the 4th quarter valued at $109,000. Institutional investors own 62.94% of the company’s stock.

Wall Street Analyst Weigh In

BVS has been the topic of several recent analyst reports. Craig Hallum set a $15.00 price objective on Bioventus and gave the company a “buy” rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Bioventus Trading Up 3.8%

NYSE BVS opened at $6.79 on Monday. Bioventus Inc. has a 12 month low of $5.28 and a 12 month high of $14.38. The stock has a market cap of $556.40 million, a P/E ratio of -11.13 and a beta of 0.95. The stock’s fifty day moving average price is $8.09 and its 200-day moving average price is $9.81. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Insider Activity

In related news, CFO Mark Leonard Singleton sold 5,479 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the sale, the chief financial officer now owns 131,963 shares in the company, valued at approximately $1,291,917.77. This trade represents a 3.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,208 shares of company stock valued at $226,138 over the last ninety days. 32.90% of the stock is currently owned by corporate insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.